Organization
Chinook Therapeutics
7 clinical trials
Clinical trial
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA NephropathyStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)Status: Recruiting, Estimated PCD: 2026-01-19
Clinical trial
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy VolunteersStatus: Terminated, Estimated PCD: 2023-04-19
Clinical trial
BION-1301 - A Phase 1, Open-label, Single Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Japanese Healthy SubjectsStatus: Completed, Estimated PCD: 2022-12-16
Clinical trial
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular DiseasesStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal FunctionStatus: Active (not recruiting), Estimated PCD: 2023-09-07